Skip to main content

Advertisement

Table 2 Univariate analysis

From: Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

  Non-rituximab-RIC
N = 1022
Rituximab-containing RIC
N = 379
 
Outcomes N eval Prob (95%CI) N eval Prob (95%CI) p value
ANC recovery >500/uL 1013   379   
 28 days   97 (96–98)%   98 (96–99)% 0.51
 100 days   99 (98–99)%   99 (97–100)% 0.99
Platelet recovery ≥ 20/uL 986   378   
 28 days   90 (88–92)%   90 (87–93)% 0.66
 100 days   96 (94–97)%   96 (93–97)% 0.79
Acute GVHD (II IV) 1004   377   
 180 days   37 (34–40)%   43 (38–48)% 0.03
Acute GVHD (III IV) 1004   377   
 180 days   13 (11–16)%   16 (12–19)% 0.29
Chronic GVHD 982   369   
 1 year   44 (41–48)%   41 (36–47)% 0.32
 2 years   53 (50–57)%   53 (47–58)% 0.79
NRM 988   367   
 1 year   14 (12–16)%   13 (10–17)% 0.78
 3 years   21 (18–24)%   20 (16–24)% 0.68
Relapse/progression 988   367   
 1 year   26 (23–29)%   19 (15–23)% 0.004
 3 years   32 (29–35)%   24 (20–29)% 0.005
PFS 988   367   
 1 year   60 (57–63)%   68 (63–72)% 0.007
 3 years   47 (44–50)%   56 (51–61)% 0.005
Mortality (inverse of OS) 1022   379   
 1 year   70 (67–73)%   76 (71–80)% 0.04
 3 years   56 (53–59)%   64 (59–68)% 0.01
  1. Probabilities of neutrophil and platelet recovery, platelet recovery, acute GVHD, chronic GVHD, treatment-related mortality, and progression/relapse were calculated using the cumulative incidence estimate. Progression-free survival and overall survival was calculated using the Kaplan-Meier product limit estimate
  2. Abbreviations: ANC absolute neutrophil count, GVHD graft-versus-host disease, PROB probability, CI confidence interval, N eval number evaluable, NRM non-relapse mortality, PFS progression free survival, RIC reduced-intensity conditioning, OS overall survival